Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8008) clinical trials

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

Phase N/A

The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition of crizotinib may help prevent ...

Phase

The purpose of this study is to evaluate the safety and tolerability of INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Phase N/A

People with Breast Cancer are asked to participate in a research study being conducted by White Plains Hospital.

Phase N/A

Consider a research study for uterine fibroids. The Asteroid Studies are research studies evaluating the safety and effectiveness of an investigational oral medication for uterine fibroids.

Phase N/A

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor or a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

Phase

Advanced tumors evade host immune responses by down regulation of major histocompatibility complex (MHC) molecules and tumor antigens and by creating an immune suppressive microenvironment around the tumor. Histone deacetylases (HDACs) have been implicated in the epigenetic regulation of innate and adaptive immunity. Increasing evidence supports the proposal that spectrum-selective ...

Phase N/A

The objective of this study is to describe the occurrence of AEs leading to dose reduction following afatinib treatment in NSCLC patients with common EGFR mutations (Deletion 19 and/or L858R) who are 70 years of age or older.

Phase

People with well-differentiated metatatic and/or unresectable typical or atypical lung neuroendocrine tumors are asked to participate in a research study being conducted by Montefiore Medical Center

Phase N/A